Lumos Diagnostics Holdings Ltd. (AU:LDX)
ASX:LDX
Want to see AU:LDX full AI Analyst Report?
LDX Stock Chart & Stats
AU$0.32
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.32
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.33
Previous CloseN/A
Volume213.94K
Average Volume (3M)5.63M
Market Cap
AU$97.57M
Enterprise ValueAU$71.94M
Total Cash (Recent Filing)AU$3.00M
Total Debt (Recent Filing)AU$11.85M
Price to Earnings (P/E)―
Beta1.92
Next Earnings
Sep 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding929,211,100
10 Day Avg. Volume3,659,446
30 Day Avg. Volume5,628,467
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.96
Price to Sales (P/S)0.97
P/FCF Ratio-1.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)AU$20.86M
Bulls Say, Bears Say
Bulls Say
Guaranteed U.S. DistributionA multi-year exclusive PHASE agreement guaranteeing at least USD 317M of sales provides durable revenue visibility and offloads U.S. go-to-market execution to a distribution partner. This underpins recurring consumables demand, aids capacity planning and reduces single-year commercial execution risk.
Reimbursement CoverageCMS reimbursement at USD 41.38 and multiple MAC agreements create a stable, commercially viable price for physician-office use. Durable reimbursement lowers adoption barriers, supports predictable per-test revenue and margin sustainability, and materially improves long-term addressable-market economics.
Improved Cash Flow & FundingPositive operating cash flow and nondilutive BARDA receipts reduce immediate liquidity pressure and lower near-term dilution risk. Improved cash conversion combined with targeted grants/funding provides a firmer financial base to run trials, initial U.S. commercialization and to postpone larger equity raises while scaling.
Bears Say
High LeverageMaterial leverage (debt/equity ~1.13) constrains financial flexibility and raises refinancing and interest burdens. Over a multi-month horizon this reduces the firm's ability to invest opportunistically, absorb timing shocks from commercial rollouts, and increases the dependency on external financing to scale.
CLIA Waiver DependencyThe commercial ramp and practical benefits of the PHASE deal rely on a CLIA waiver. Without it, point-of-care in-office use and high-volume placements remain limited, making material revenue realization and durable market penetration conditional on regulatory timing and approval outcomes.
Profitability & Capacity Funding NeedsDespite improvement, adjusted EBITDA remains negative and management expects capital investments to expand manufacturing beyond year two of the PHASE agreement. This creates execution risk: the company must secure funding or reallocate cash to scale production while simultaneously closing the profitability gap.
Lumos Diagnostics Holdings Ltd. News
LDX FAQ
What was Lumos Diagnostics Holdings Ltd.’s price range in the past 12 months?
Lumos Diagnostics Holdings Ltd. lowest share price was AU$0.03 and its highest was AU$0.33 in the past 12 months.
What is Lumos Diagnostics Holdings Ltd.’s market cap?
Lumos Diagnostics Holdings Ltd.’s market cap is AU$97.57M.
When is Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date?
Lumos Diagnostics Holdings Ltd.’s upcoming earnings report date is Sep 01, 2026 which is in 85 days.
How were Lumos Diagnostics Holdings Ltd.’s earnings last quarter?
Lumos Diagnostics Holdings Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.009 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.009.
Is Lumos Diagnostics Holdings Ltd. overvalued?
According to Wall Street analysts Lumos Diagnostics Holdings Ltd.’s price is currently Overvalued.
Does Lumos Diagnostics Holdings Ltd. pay dividends?
Lumos Diagnostics Holdings Ltd. does not currently pay dividends.
What is Lumos Diagnostics Holdings Ltd.’s EPS estimate?
Lumos Diagnostics Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lumos Diagnostics Holdings Ltd. have?
Lumos Diagnostics Holdings Ltd. has 929,211,100 shares outstanding.
What happened to Lumos Diagnostics Holdings Ltd.’s price movement after its last earnings report?
Lumos Diagnostics Holdings Ltd. reported an EPS of -AU$0.009 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 7.843%.
Which hedge fund is a major shareholder of Lumos Diagnostics Holdings Ltd.?
Currently, no hedge funds are holding shares in AU:LDX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lumos Diagnostics Holdings Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:LDX Sentiment 90%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$119.4K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
551.51%
12-Months-Change
Fundamentals
Return on Equity
-164.12%
Trailing 12-Months
Asset Growth
-26.05%
Trailing 12-Months
Company Description
Lumos Diagnostics Holdings Ltd.
Lumos Diagnostics Holdings Limited, a contract research and development company, develops and commercializes rapid point-of-care (POC) diagnostic tests which are primarily focuses on the diagnosis and management of infectious diseases in the United States and Australia. The company products include FebriDx, a POC diagnostic test for detecting and differentiating viral and bacterial respiratory infections; ViraDx, a three-in-one POC test for influenza A, influenza B, and COVID-19.; and CoviDx, a rapid antigen test for COVID-19. It also offers desktop readers, disposable readers, and Lumos Leelu readers. Lumos Diagnostics Holdings Limited was founded in 2004 and is based in Melbourne, Australia.
Technical Analysis
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Genetic Signatures Ltd.
―
Inoviq Ltd
―
Microba Life Sciences Limited
―
Options Prices
Currently, No data available
---